Journal profile · Biochemistry, Genetics and Molecular Biology-Molecular Medicine
Pharmacogenomics & Personalized Medicine
ISSN 1178-7066 · Dove Medical Press · New Zealand
Pharmacogenomics & Personalized Medicine: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.38; fully open access; APC about USD 3,565; median 130 days to acceptance (51 articles, last 24 months); acceptance rate 9% (journal website); 23 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Pharmacogenomics & Personalized Medicine is published by Dove Medical Press and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Pharmacogenetics and Drug Metabolism, Ferroptosis and cancer prognosis and Cancer-related molecular mechanisms research, together about 32.8% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Editor-in-Chief: Dr Martin H Bluth Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open-access journal characterizing the influence of human genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability. Pharmacogenomics and Personalized Medicine will no longer consider meta-analyses for publication. Pharmacogenomics and Personalized Medicine aims to serve both the academic and industrial communities and accepts research on the following topics: Genomic and proteomic profiling Genetics and drug metabolism Genetic variability in drug toxicity and efficacy Genetic-based vaccine development Targeted drug identification, discovery and delivery Optimizing drug selection and dosage based on patient's genetic profile Drug related morbidity and mortality intervention Advanced disease screening and targeted therapeutic intervention Practical and organizational challenges in the development and implementation of personalized medicine programs Patient satisfaction and preference Health economic evaluations of personalized medicine When considering submission of a paper utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.), authors should ensure that such studies add significantly to the body of knowledge about a specific disease or relevant phenotype and that they are validated using the authors’ own data through replication in an independent sample set and functional follow-up. Bioinformatics studies should also conform to these criteria. Animal-only studies will not be considered. The journal is open to embrace breakthrough research papers so to enhance development of the subject. To increase the diversity of research aspects, the journal aims at various authorship and readership audiences. The journal welcomes submitted papers covering original research, clinical studies, reviews and evaluations, guidelines, policy papers, expert opinion and commentary, case reports and extended reports. Updated 5 August 2025
From the journal's Aims & Scope
Research area (LetPub): Biochemistry, Genetics and Molecular Biology-Molecular Medicine
Editor-in-chief Martin H BluthPublisher website
Editorial board by country: none in mainland China; most named United States 15, Australia 4, Japan 2, Germany 2, Netherlands 2 (25 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics19.9%
- Ferroptosis and cancer prognosisMedicine7.3%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology5.6%
- Genetic Associations and EpidemiologyBiochemistry, Genetics and Molecular Biology5.3%
- Drug Transport and Resistance MechanismsMedicine4.4%
- Antiplatelet Therapy and Cardiovascular DiseasesMedicine4%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology3.7%
- Genomics and Rare DiseasesBiochemistry, Genetics and Molecular Biology3.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
SJR, CiteScore, Impact FactorPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.38LetPub ·
- Impact factor (publisher) 2025
- 2.2Publisher website ·
- 5-year impact factor (publisher)
- 4.8Publisher website ·
- CiteScore 2026-06
- 4.8LetPub ·
- CiteScore (publisher) 2025
- 0.74Publisher website ·
- SJR 2026-06
- 0.73LetPub ·
- SNIP 2026-06
- 0.74LetPub ·
- h-index
- 46OpenAlex ·
- i10-index
- 298OpenAlex ·
- 2-year mean citedness
- 2.27OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 98.73%LetPub ·
Volume
- Articles per year
- 23LetPub ·
- Downloads per year (publisher)
- 72,812Publisher website ·
Articles by year OpenAlex count · 708 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 18 | 18 | 1 |
| 2025 | 23 | 23 | 50 |
| 2024 | 44 | 44 | 142 |
| 2023 | 97 | 97 | 593 |
| 2022 | 82 | 82 | 669 |
| 2021 | 155 | 155 | 1,506 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
130 daysMedian, submission to acceptance · P25–P75 114 days – 149 days
- Acceptance to online
- median 18 days (51 articles)
- Submission to online
- median 151 days
- Sample
- 51 articles with submission and acceptance dates (52 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Acceptance rate (publisher)
- 9%Publisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,565 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,836 | — | — | |
| LetPub | USD 3,300 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted3
- case reportAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- original researchOriginal Research Five VEGFA Polymorphisms and Bleeding During Warfarin Therapy in a Saudi Population: An Exploratory Retrospective Cohort StudyLength not stated
- reviewAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
Policy excerpts from the journal's websitePublication ethics, Open access
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Dove Medical Press
- Country or region
- New Zealand
- Language
- English
- ISSN
- 1178-7066
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Pharmacogenomics & Personalized Medicine
What CAS zone is Pharmacogenomics & Personalized Medicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, Pharmacogenomics & Personalized Medicine is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Pharmacogenomics & Personalized Medicine?
The latest impact factor listed by LetPub is 2.38; CiteScore 4.8, h-index 46.
How long does peer review take at Pharmacogenomics & Personalized Medicine?
Based on the dates recorded on 51 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 130 days (interquartile range 114–149 days); authors report an average review time of about 16 weeks; the journal's website gives an acceptance rate of 9%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Pharmacogenomics & Personalized Medicine based?
Of the 25 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (15), Australia (4) and Japan (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Pharmacogenomics & Personalized Medicine?
According to LetPub and DOAJ records, Pharmacogenomics & Personalized Medicine is indexed in SCIE, Scopus and DOAJ.
Is Pharmacogenomics & Personalized Medicine open access, and what is the APC?
Pharmacogenomics & Personalized Medicine is a fully open-access journal. APC about USD 3,565.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .